1131-142 Predictors of left atrial appendage thrombogenesis in patients undergoing transesophageal echocardiography-guided cardioversion for atrial fibrillation and flutter  by Alatawi, Faisal O et al.
348A ABSTRACTS - Noninvasive Imaging JACC March 3, 2004
No
ni
nv
as
iv
e 
Im
ag
in
g
1131-142 Predictors of Left Atrial Appendage Thrombogenesis in 
Patients Undergoing Transesophageal 
Echocardiography-Guided Cardioversion for Atrial 
Fibrillation and Flutter
Faisal O. Alatawi, Joseph Malouf, Chandrasekaran Krishnaswarmy, Saeed A. Al Ahmari, 
Brenda S. Moon, Charles J. Bruce, Naser M. Ammash, Mayo Clinic, Rochester, MN
Background: The clinical and echocardiographic predictors of left atrial appendage (LAA)
thrombogenesis in patients (pts) with non rheumatic atrial fibrillation (NRAF) or flutter
AFL remain unclear.
Methods:. Between May 2000 and 2003 ,75 patients with LAA thrombi or dense sponta-
neous echo contrast (DSEC) prior to scheduled transesophageal echocardiography
(TEE) guided cardioversion (group 1) were compared to a matched group (for age, gen-
der, diabetes, type of arrhythmia, sedation during TEE) without LAA thrombi or DSEC
(group2). pts with mitral valve stenosis, congenital heart disease, or prosthetic valve,
were excluded..
Results:. Univariate predictors of LAA thrombi and DSEC are summarized in the table
below. 
On multivariate analysis only NYHA class III& IV and LAA emptying velocity < 20 cm \ s 
were independent predictors of LAA thrombi and \or LAA DSEC.
Conclusion: In patients scheduled to undergo TEE guided cardioversion., both advanced 
symptoms of heart failure and severe mechanical left atrial appendage dysfunction are 
independently predictive of a thrombogenic milieu within the LAA
1131-143 The Fate of Left Atrial Thrombi: A Prospective and Serial 
Follow-Up Over Three Years With Transesophageal 
Echocardiography and Cerebral Magnetic Resonance 
Imaging
Peter Bernhardt, Harald Schmidt, Christoph Hammerstingl, Berndt Luederitz, Heyder 
Omran, University of Bonn, Bonn, Germany
Background: Patients (pts) with atrial fibrillation (AF) and atrial thrombi are at a high risk
for stroke. However, there are no prospective long-term data on the prognosis of pts
available. The aims of this prospective study were (1) to assess the prognosis of pts with
atrial thrombi and (2) to evaluate the incidence of cerebral embolism and death. 
Methods: 21 consecutive pts with AF and atrial thrombi located in the left atrial append-
age (LAA) were enrolled in our study. All pts received oral anticoagulation during the
study period (INR>2 was regarded as effective anticoagulation). The pts underwent fol-
lowing examinations during the three years observation period: transthoracic (TTE) and
transesophageal echocardiography (TEE), cerebral MRI, control of the anticoagulation
status and neurological examination.
Results: 2 [10%] pts died due to cerebrovascular events during the follow-up period. 8
[38%] pts had cerebral embolism as documented with neuological deficits during the
observation period. 15 [71%] thrombi dissolved under continued oral anticoagulation. Pts
with and without embolism did not differ for age, sex, cardiovascular risk factors and his-
tory of embolism. Pts with thrombus resolution had significantly smaller thrombi (1.3 ±
0.6 cm vs. 1.7 ± 0.6 cm length and 0.6 ± 0.2 vs. 1.0 ± 0.5 width, p=0.03) and less often
echogenic thrombi (8 [53%] vs. 6 [100%], p=0.02).
Conclusion: Pts with AF and LAA thrombi have a high long term risk for cerebral embo-
lism and/or death [52%] (17% per year). A high percentage of thrombi disappear under
continued oral anticoagulation therapy [71%]. Independent predictors for thrombus reso-
lution are thrombus size and echogenicity.
1131-144 Significant Mitral Regurgitation Is Protective Against 
Left Atrial Spontaneous Echo Contrast and 
Thrombogenesis in Atrial Fibrillation: An ACUTE Trial 
Ancillary Study
John A. Sallach, Richard A. Grimm, Susan E. Jasper, Jianbo Li, Elizabeth A. Lieber, 
Allan L. Klein, Cleveland Clinic Foundation, Cleveland, OH
Background:The relationship between mitral regurgitation (MR) and left atrial spontane-
ous echo contrast (LA-SEC)/thrombus (THR) in atrial fibrillation (AF) remains controver-
sial. We sought to determine if significant MR protects against the development of LA-
SEC/THR in AF.
Methods: The Assessment of Cardioversion Using Transesophageal Echocardiography
(ACUTE) Trial, randomized 1,222 patients with AF to TEE-guided cardioversion or con-
ventional treatment. TEE with 6 month follow-up was available in 469 (38%) patients.
TEEs were evaluated for LA-THR and LA-SEC was graded as absent, mild or severe.
Patients were divided according to the presence of MR on TEE (MR > 3+ was significant
and MR < 2+ was insignificant). Baseline clinical variables and TEE parameters were
compared between these two groups.
Results: MR < 2+ was found in 443 (94.5%) patients (mean age 66 ± 12 yrs) while 26
(5.5%) patients (mean age 64 ± 13 yrs) had MR > 3+. There were no differences in base-
line characteristics with the exception of increased AF duration in patients with MR < 2+
(13 [5-48] days vs. 10 [5-34] days, p=0.03). On TEE, LA-SEC/THR was noted in 252
(59%) patients with MR < 2+ compared to only 6 (27%) patients with MR > 3+ (p=0.001)
(Table 1). After adjusting for confounders MR > 3+ was found to be protective against LA-
SEC/THR.
Conclusions: In AF, significant MR is protective against the formation of LA-SEC/THR.
These findings should be considered in the TEE risk stratification of AF patients.
1131-145 Impact of Percutaneous Left Atrial Appendage 
Transcatheter Occlusion Device on Left Atrial Structure 
and Function: Six-Month Echocardiographic Follow-Up
Ibrahim R. Hanna, Gerald P. Kolm, Randolph Martin, Peter Block, Emory University 
School of Medicine, Atlanta, GA
Background: Percutaneous left atrial appendage transcatheter occlusion (PLAATO) is a
novel device designed to seal the neck of the left atrial appendage with the purpose of
reducing embolization in patients with atrial fibrillation intolerant of coumadin. The impact
of deployment of this device on adjacent structures has not been reported.
Methods: Patients participating in the ongoing study for evaluation of PLAATO in stroke
prevention at 2 hospitals were enrolled. Transesophageal echocardiograms at baseline,
1, and 6 months, were reviewed to measure left atrial (LA) and left upper pulmonary vein
(LUPV) dimensions, degree of mitral regurgitation (MR), stability and flow around the
device, peak mitral valve (MV) E-wave velocity, and peak systolic and diastolic flow veloc-
ities in the LUPV. Data were analyzed by a linear mixed model for repeated measures.
Results: 11 patients (mean age of 72 ± 7 years) completed 6 months of follow-up. LUPV
diameter (mean: 1.55, 1.61, 1.54 cm, p=0.13), peak systolic (mean: 0.38, 0.34, 0.31 m/
sec, p=0.72), and diastolic flow velocities (mean: 0.39, 0.40, 0.42 m/sec, p=0.46) did not
differ over the follow-up period. LA size, degree of MR, and MV peak E-wave velocities
(mean: 0.94, 0.94, 0.82 m/sec, p=0.58) showed no significant change from baseline. The
devices remained stable with minimal residual flow around them.
Conclusion: PLAATO achieved an adequate seal of the neck of the left atrial appendage
without significant effect on the structure or function of the LA and LUPV. 
1131-146 Serial Echocardiographic Follow-Up of Percutaneous 
Left Atrial Appendage Transcatheter Occlusion 
(PLAATOTM) in Patients With Atrial Fibrillation
Athena Poppas, Toshiko Nakai, Horst Sievert, Linda Crouse, Bruce L. Macrum, Kimberly 
Krabill, Sandra Gan, Randolph Martin, Heyder Omran, Mauro Pepi, Fabio Sgura, 
Christian Seiler, Linda Clarke, Richard Kutnick, David Rubenson, Bryan Dias, Mark 
Reisman, Rhode Island Hospital, Providence, RI
Background: In patients (pts) with non-rheumatic AF, over 90% of thrombi form in the
left atrial appendage (LAA). For pts who cannot take warfarin, a novel transcather device
was designed to mechanically occlude the LAA.
Methods: 101 pts (age = 71±7 yrs) with AF, high risk for thromboembolism, via clinical
(CHF, DM, HTN, TIA/CVA) or TEE (dense spontaneous echo contrast or LAA emptying
velocities <20 cm/sec) criteria were enrolled at 12 sites. Screening TEE ruled out LAA
clot. A PLAATO device (ev3) was delivered under fluoroscopic and TEE guidance to the
LAA through a 12 Fr transseptal sheath. TTEs were performed at baseline 1 week, 1 mo,
6 mos and 12 mos of follow-up. Color Doppler assessed mitral regurgitation and shunt-
ing.
Results: 64 pts had 151 TTEs evaluated by an independent core laboratory (AP). Base-
line LVEF = 51.2±9.4% and LA diameter = 4.6±0.6 cm. Mitral regurgitation (MR) was
trace-mild in 77%, moderate in 9%, severe in 1%. No pre-specified device complications
were noted on f/u: worsening mitral regurgitation; device migration or perforation; mobile
thrombus. Of 101 pts, 5 intra-procedural pericardial effusions were noted and treated;
covariate Control
N=75
Study
N=75
P value
Duration of arrhythmia >4weeks % 41% 74% <0.0001
New York heart association (NYHA) class III &IV % 12.5% 39.5% 0.0004
Prior history of transient ischemic attack or 
cerebrovascular accident %
1.3% 10.6% 0.016
LAA emptying velocity < 20cm \s % 1.5% 92.5% <0.0001
Left ventricular ejection fraction, mean ± SD 53 ±13 41±16 <0.0001
systolic fraction of pulmonary flow velocity time 
integral (cm) mean ±SD
0.45 ± 0.12 0.3 ±1 0.08 <0.0001
Table 1. Transesophageal Echocardiogram Findings According to Presence or 
Absence of Significant MR
MR <= 2+(n = 443) MR => 3+(n = 26) p Value
Any LA-SEC 57% 23% <0.001
Mild LA-SEC 40% 12% 0.007
Severe LA-SEC 15% 12% 0.830
LA-THR 13% 4% 0.18
LA-SEC/THR 59% 28% 0.001
Baseline
mean ± sd (n)
1 month
mean ± sd (n)
6 months
mean ± sd (n)
p value
Heart rate
(beats/mn)
78.5 ± 12.5 (11) 81.7 ±13.3 (10) 77.3 ± 13.2 (10) 0.584
LUPV diameter
(cm)
1.55 ± 0.19 (11) 1.61 ± 0.16 (9) 1.54 ± 0.17 (10) 0.13
MV E wave*
(m/sec)
0.94 ± 0.35 (10) 0.94 ± 0.20 (6) 0.82 ± 0.47 (8) 0.581
LUPV S-wave*
(m/sec)
0.38 ± 0.22 (11) 0.34 ± 0.23 (8) 0.31 ± 0.14 (9) 0.716
LUPV D-wave*
(b>m/sec)
0.39 ± 0.14 (10) 0.40 ± 0.19 (8) 0.42 ± 0.18 (9) 0.463
